About Slingshot Biosciences
Founded in 2012, Slingshot Biosciences develops synthetic cell mimic technologies that provide standardised reference materials for flow cytometry and cell-based analysis. The company engineers particles designed to replicate the biological, optical and fluorescence characteristics of cells, enabling researchers to improve assay reproducibility and reduce variability associated with donor-derived or cultured cell controls. Its technologies support applications including immunophenotyping, spectral unmixing, compensation, viability assessment, instrument standardisation and cell therapy research, helping laboratories generate more consistent and comparable flow cytometry data across instruments, operators and sites.
The company’s product portfolio includes the SpectraComp®, ViaComp®, FlowCytes®, ScatterBridge®, PhenoCytes™, QuantCytes™ and TruCytes™ product families, which support compensation controls, instrument calibration, viability testing, biomarker analysis and functional assay development. Slingshot Biosciences also provides custom cell mimic solutions tailored to specific biomarkers and workflow requirements. These products are used in academic research, biopharmaceutical development, clinical assay development and cell therapy manufacturing workflows where robust reference materials are required for assay validation and quality control.
Europa Biosite subsidiaries distribute Slingshot Biosciences products in Austria, Belgium, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxemburg, Netherlands, Norway, Sweden, Switzerland, the United Kingdom and the USA.